ENTRY       hsa05310                    Pathway
NAME        Asthma - Homo sapiens (human)
DESCRIPTION Asthma is a complex syndrome with many clinical phenotypes in both adults and children. Its major characteristics include a variable degree of airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Inhaled allergens encounter antigen presenting cells (APC) that line the airway. Upon recognition of the antigen and activation by APC, naive T cells differentiate into TH2 cells. Activated TH2 stimulate the formation of IgE by B cells. IgE molecules bind to IgE receptors located on mast cells. The crosslinking of mast-cell-bound IgE by allergens leads to the release of biologically active mediators (histamine, leukotrienes) by means of degranulation and, so, to the immediate symptoms of allergy. Mast cells also release chemotactic factors that contribute to the recruitment of inflammatory cells, particularly eosinophils, whose proliferation and differentiation from bone marrow progenitors is promoted by IL-5. The activation of eosinophils leads to release of toxic granules and oxygen free radicals that lead to tissue damage and promote the development of chronic inflammation.
CLASS       Human Diseases; Immune disease
PATHWAY_MAP hsa05310  Asthma
DISEASE     H00079  Asthma
DRUG        D04923  Mepolizumab (USAN/INN)
            D05251  Omalizumab (USAN/INN)
            D09897  Enokizumab (USAN/INN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        102723407  IGH; immunoglobulin heavy variable 4-38-2-like [KO:K06856]
            2205  FCER1A; Fc epsilon receptor Ia [KO:K08089]
            2206  MS4A2; membrane spanning 4-domains A2 [KO:K08090]
            2207  FCER1G; Fc epsilon receptor Ig [KO:K07983]
            3108  HLA-DMA; major histocompatibility complex, class II, DM alpha [KO:K06752]
            3109  HLA-DMB; major histocompatibility complex, class II, DM beta [KO:K06752]
            3111  HLA-DOA; major histocompatibility complex, class II, DO alpha [KO:K06752]
            3112  HLA-DOB; major histocompatibility complex, class II, DO beta [KO:K06752]
            3113  HLA-DPA1; major histocompatibility complex, class II, DP alpha 1 [KO:K06752]
            3115  HLA-DPB1; major histocompatibility complex, class II, DP beta 1 [KO:K06752]
            3117  HLA-DQA1; major histocompatibility complex, class II, DQ alpha 1 [KO:K06752]
            3118  HLA-DQA2; major histocompatibility complex, class II, DQ alpha 2 [KO:K06752]
            3119  HLA-DQB1; major histocompatibility complex, class II, DQ beta 1 [KO:K06752]
            3120  HLA-DQB2; major histocompatibility complex, class II, DQ beta 2 [KO:K06752]
            3122  HLA-DRA; major histocompatibility complex, class II, DR alpha [KO:K06752]
            3123  HLA-DRB1; major histocompatibility complex, class II, DR beta 1 [KO:K06752]
            3125  HLA-DRB3; major histocompatibility complex, class II, DR beta 3 [KO:K06752]
            3126  HLA-DRB4; major histocompatibility complex, class II, DR beta 4 [KO:K06752]
            3127  HLA-DRB5; major histocompatibility complex, class II, DR beta 5 [KO:K06752]
            3562  IL3; interleukin 3 [KO:K04736]
            3565  IL4; interleukin 4 [KO:K05430]
            3567  IL5; interleukin 5 [KO:K05428]
            3578  IL9; interleukin 9 [KO:K05432]
            3586  IL10; interleukin 10 [KO:K05443]
            3596  IL13; interleukin 13 [KO:K05435]
            5553  PRG2; proteoglycan 2, pro eosinophil major basic protein [KO:K10786]
            6037  RNASE3; ribonuclease A family member 3 [KO:K10787] [EC:3.1.27.-]
            6356  CCL11; C-C motif chemokine ligand 11 [KO:K16597]
            7124  TNF; tumor necrosis factor [KO:K03156]
            8288  EPX; eosinophil peroxidase [KO:K10788] [EC:1.11.1.7]
            958  CD40; CD40 molecule [KO:K03160]
            959  CD40LG; CD40 ligand [KO:K03161]
COMPOUND    C00388  Histamine
            C00696  Prostaglandin D2
            C02166  Leukotriene C4
            C04598  2-Acetyl-1-alkyl-sn-glycero-3-phosphocholine
            C05951  Leukotriene D4
REFERENCE   PMID:11172168
  AUTHORS   Busse WW, Lemanske RF Jr.
  TITLE     Asthma.
  JOURNAL   N Engl J Med 344:350-62 (2001)
            DOI:10.1056/NEJM200102013440507
REFERENCE   PMID:11477111
  AUTHORS   Renauld JC.
  TITLE     New insights into the role of cytokines in asthma.
  JOURNAL   J Clin Pathol 54:577-89 (2001)
            DOI:10.1136/jcp.54.8.577
REFERENCE   PMID:10719286
  AUTHORS   Romagnani S.
  TITLE     The role of lymphocytes in allergic disease.
  JOURNAL   J Allergy Clin Immunol 105:399-408 (2000)
            DOI:10.1067/mai.2000.104575
REFERENCE   PMID:17976144
  AUTHORS   Averbeck M, Gebhardt C, Emmrich F, Treudler R, Simon JC.
  TITLE     Immunologic principles of allergic disease.
  JOURNAL   J Dtsch Dermatol Ges 5:1015-28 (2007)
            DOI:10.1111/j.1610-0387.2007.06538.x
REFERENCE   PMID:11686879
  AUTHORS   Conroy DM, Williams TJ.
  TITLE     Eotaxin and the attraction of eosinophils to the asthmatic lung.
  JOURNAL   Respir Res 2:150-6 (2001)
            DOI:10.1186/rr52
REFERENCE   PMID:17133123
  AUTHORS   Effros RM, Nagaraj H.
  TITLE     Asthma: new developments concerning immune mechanisms, diagnosis and treatment.
  JOURNAL   Curr Opin Pulm Med 13:37-43 (2007)
            DOI:10.1097/MCP.0b013e3280108757
REFERENCE   PMID:18274560
  AUTHORS   Barnes PJ.
  TITLE     Immunology of asthma and chronic obstructive pulmonary disease.
  JOURNAL   Nat Rev Immunol 8:183-92 (2008)
            DOI:10.1038/nri2254
REFERENCE   PMID:18274559
  AUTHORS   Holgate ST, Polosa R.
  TITLE     Treatment strategies for allergy and asthma.
  JOURNAL   Nat Rev Immunol 8:218-30 (2008)
            DOI:10.1038/nri2262
REFERENCE   PMID:12093011
  AUTHORS   Valenta R.
  TITLE     The future of antigen-specific immunotherapy of allergy.
  JOURNAL   Nat Rev Immunol 2:446-53 (2002)
            DOI:10.1038/nri824
REFERENCE   PMID:17364144
  AUTHORS   Trivedi SG, Lloyd CM.
  TITLE     Eosinophils in the pathogenesis of allergic airways disease.
  JOURNAL   Cell Mol Life Sci 64:1269-89 (2007)
            DOI:10.1007/s00018-007-6527-y
REFERENCE   PMID:10811837
  AUTHORS   Heinecke JW.
  TITLE     Eosinophil-dependent bromination in the pathogenesis of asthma.
  JOURNAL   J Clin Invest 105:1331-2 (2000)
            DOI:10.1172/JCI10072
REL_PATHWAY hsa04060  Cytokine-cytokine receptor interaction
            hsa04514  Cell adhesion molecules
            hsa04612  Antigen processing and presentation
            hsa04630  JAK-STAT signaling pathway
            hsa04660  T cell receptor signaling pathway
            hsa04662  B cell receptor signaling pathway
            hsa04664  Fc epsilon RI signaling pathway
KO_PATHWAY  ko05310
///
